In the first phase (i.e. the manufacturing and launching new OTC products), Juwel BioPharma will invest around 5 million euros in the research and development that help with diseases of the central nervous system, the respiratory tract, the gastrointestinal tract, the musculoskeletal system, and the urogenital tract. The second phase will be focused on preclinical to clinical research targeting neurological disorders, urological disorders, gastrointestinal disorders, and musculoskeletal disorders with significant unmet needs.
Cannabis plants generate a vast array of intricate molecules known as cannabinoids. These compounds serve diverse and significant functions in regulating the plant’s interactions with the environment. Furthermore, many of these compounds possess valuable medicinal properties that can be lifesaving, making them utilized in both traditional and modern medicine. On October 7th, 2021, our company received cannabis license from the German Federal Institute for Drugs and Medical Products (BfArM). This license enables us to engage in cultivation and R&D activities related to cannabis.
In order to guarantee the effectiveness of phytopharmaceutical products, they should be formulated in a convenient form for effortless ingestion (e.g., tablets or soft capsules) or application to the intended area (e.g., creams, ointments, or suppositories). Additionally, these products should possess a reliable shelf life, maintaining their vital qualities including active ingredient content, appearance, odor, and taste throughout the intended period of usage.
